ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis Challenges Use Of Avastin In UK To Treat Eye Disease

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- Swiss drug maker Novartis (NVS) is challenging the use of a unlicensed cheaper medicine to treat an eye disease in the U.K. as an alternative to its drug Lucentis. "It is unacceptable to put the safety of patients at risk through the widespread use of an unlicensed treatment when a licensed medicine is available," Novartis said in a statement. "It undermines the regulatory process that was introduced to safeguard patients." Novartis also said there is "emerging evidence" of potential safety concerns on the use of Avastin, or bevacizumab, to treat a neovascular form of age related macular degeneration, known as wet AMD. The BBC Tuesday said Novartis was seeking a judicial review of the policy to pay for Avastin on the publicly funded National Health Service, after the NHS in four areas in the south of England agreed last year that Avastin could be prescribed for the condition. Novartis declined to comment on whether it was seeking the review. Lucentis, Novartis' best-selling eye drug which generated $2.05 billion in sales in 2011, is recommended for use by the NHS to treat wet age-related macular degeneration. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
10/10/201404:08:25Oxford Biomedica Inks New Collaboration Pact with Novartis
10/03/201411:32:27EU Approves Acquisition of Novartis Animal Health Division by...
09/22/201412:43:39Germany's Merck to Buy Sigma-Aldrich for $17 Billion--2nd Update
09/01/201412:45:13EUROPE MARKETS: Novartis Climbs, Iliad Drops: European Movers
09/01/201412:01:47EUROPE MARKETS: Novartis Up, Iliad Drops: European Movers
09/01/201408:27:44Ruble Hits New Record Low Against Dollar
08/29/201412:46:16Zurich Stocks Rise; Novartis Drug Test Results Eyed -- Market...
08/18/201412:40:12Zurich Stocks Mostly Higher; Swisscom Down -- Market Talk
08/01/201412:26:48LONDON MARKETS: FTSE 100 Slumps For Third Day As Miners, Banks...
07/28/201402:37:21Novartis Gets EU Approval For Glaucoma Drug
07/25/201407:44:11Drug Companies Oppose Moves to Reimburse Off-Label Medicine
07/17/201418:27:37ADR Shares End Lower; SAP Shares Trade Actively
07/16/201418:17:45Novartis 2Q Results -- Forecast
07/15/201417:53:10ADR Shares End Mixed; British American Tobacco Shares Trade Actively
07/15/201416:58:23Novartis, Google Team Up on Lenses -- Update
07/07/201415:20:45Novartis Wins 'Breakthrough' Status for Leukemia Treatment
07/02/201417:32:10ADR Shares End Mixed; Telefonica, Veolia Environnement Shares...
06/19/201409:25:15Actavis Generic Exelon Patch Found to Infringe on Patents
06/18/201417:07:21ADR Shares End Higher
05/29/201409:03:30EUROPE MARKETS: European Stocks Seesaw; Kingfisher Down After...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad